New treatment for AFib patients shows less tissue damage and improved outcomes, offered first at AdventHealth

Choose the health content that’s right for you, and get it delivered right in your inbox.

Dr. Nashaud Shaik performing a procedure.

Patients with the most common type of heart arrhythmia have a promising new treatment option available only in Central Florida at the AdventHealth Heart, Lung and Vascular Institute. The Pulse Field Ablation (PFA) procedure is for atrial fibrillation (AFib) patients and is designed to help them maintain a normal rhythm. This spring, AdventHealth led the inaugural Pulse Field Ablation (PFA) procedure in Central Florida and other patients have followed with the same success.

Windemere residents, Kroy Crofoot and his wife, Kelly, are grateful to their son, Ivan, who encouraged his dad to get the PFA procedure.
Windemere residents, Kroy Crofoot and his wife, Kelly, are grateful to their son, Ivan, who encouraged his dad to get the PFA procedure.

“The procedure was quick, and the recovery was fast,” said Kroy Crofoot who underwent the PFA procedure at AdventHealth Orlando in July. “I went in at 9 am, went home by 4 pm and was walking by the end of the day.”

Crofoot, who is a local furniture store owner, says he has more energy now than before the PFA procedure and he was back at work the next day, but with lifting restrictions.

“PFA is a targeted treatment that’s a safer, more efficient approach than traditional methods like radiofrequency ablation that uses heat. Heat can inadvertently damage surrounding tissues,” said Dr. Naushad Shaik, electrophysiologist and EP medical director at the AdventHealth Heart, Lung and Vascular Institute. “Our patients are learning about this new treatment and asking for it - and it has improved outcomes.”

PFA works by delivering short-duration electrical pulses to the heart tissue. The energy from the pulses kills the cells in only the cardiac tissue causing the irregular heart rate and rhythm, therefore restoring the heart to a more normal condition.

The AdventHealth team led the inaugural Pulse Field Ablation (PFA) procedure in Central Florida on March 14.
On March 14, Dr. Naushad Shaik, electrophysiologist and EP medical director (in dark green scrubs, back left), and his team led the inaugural Pulse Field Ablation (PFA) procedure in Central Florida.

According to the Centers for Disease Control and Prevention (CDC), AFib is responsible for more than 454,000 hospitalizations and roughly 158,000 deaths each year in the U.S. In addition, the CDC forecasts 12.1 million people in the United States will have AFib by 2030.

The 67-year-old credits his son, Ivan, for nudging him to get checked out by a cardiologist.

“I thought I would get a clean bill of health, instead I was told I had AFib,” said Crofoot.

He also gives high marks to Dr. Shaik and his team for helping him stay active at his work, moving furniture, and in his off time, playing tennis and pickleball.

New PFA procedure on Healthy Connections TV

Dr. Nashaud Shaik, electrophysiologist and EP medical director, discusses the new game-changing PFA procedure for AFib patients with Healthy Connections TV.

“This is a minimally invasive procedure done with tiny tubes placed in through the groin and into your heart and is performed in under an hour,” Shaik recently told Healthy Connections. “Another benefit of the PFA procedure is patients are able to come off of some of their medications.”

At his next check-up appointment, Crofoot says he hopes to be able to stop taking his blood thinner medication. For more information on the new PFA procedure, call Call407-931-5040.

Recent News

12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News
New Research Published in New England Journal of Medicine Finds That Adjuvant Pembrolizumab Extends Disease-Free Survival in Muscle-Invasive Urothelial Carcinoma

AdventHealth Clinical Research Unit (CRU) Executive Director and Medical Director of Genitourinary Oncology Guru Sonpavde, MD, co-authored an article on the AMBASSADOR Phase III clinical trial results...

Read Article about "New Research Published in New England Journal of Medicine Finds That Adjuvant Pembrolizumab Extends Disease-Free Survival in Muscle-Invasive Urothelial Carcinoma"
News
AdventHealth for Children Recruiting Patients with Fabry Disease for Phase III PERIDOT Clinical Trial Evaluating a Potential New Treatment Option

Under the leadership of Medical Director of Genomics and Personalized Health Majed Dasouki, MD, AdventHealth for Children is recruiting patients for a new Phase III clinical trial to evaluate the...

Read Article about "AdventHealth for Children Recruiting Patients with Fabry Disease for Phase III PERIDOT Clinical Trial Evaluating a Potential New Treatment Option"
View More Articles